Pulmonx Corp
NASDAQ:LUNG
P/B
Price to Book Value
Price to Book Value (P/B) ratio is a valuation multiple that measures the market's valuation of a company relative to its book value. The P/B ratio is only considered useful in practice when applied to capital-intensive businesses.
Market Cap | P/B | ||||
---|---|---|---|---|---|
US |
Pulmonx Corp
NASDAQ:LUNG
|
369.9m USD | 3.3 | ||
JP |
Hoya Corp
TSE:7741
|
6.4T JPY | 7.3 | ||
CH |
Alcon AG
SIX:ALC
|
36.2B CHF | 1.9 | ||
DK |
Coloplast A/S
CSE:COLO B
|
189.4B DKK | 12.5 | ||
US |
Align Technology Inc
NASDAQ:ALGN
|
21.6B USD | 5.7 | ||
US |
Cooper Companies Inc
NYSE:COO
|
18.6B USD | 2.4 | ||
KR |
H
|
HLB Inc
KOSDAQ:028300
|
13.5T KRW | 25.8 | |
CN |
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
60.4B CNY | 8 | ||
UK |
ConvaTec Group PLC
LSE:CTEC
|
5.3B GBP | 3.9 | ||
US |
DENTSPLY SIRONA Inc
NASDAQ:XRAY
|
5.9B USD | 1.8 | ||
US |
Lantheus Holdings Inc
NASDAQ:LNTH
|
5.3B USD | 5.6 |
P/B Forward Multiples
Forward P/B multiple is a version of the P/B ratio that uses forecasted equity for the P/B calculation. 1-Year, 2-Years, and 3-Years forwards use equity forecasts for 1, 2, and 3 years ahead, respectively.